Mani, I'm not saying it will go this way, but in the UK they've made provisions for their citizens to get DCVax-L for other solid cancers. I believe it's clear that they are thinking about it, if the delays have been so additional supportive evidence for tumor agnostic could be provided, I still think it's possible. As I see it, almost all evidence for this would come from within the UK where Dr. Ashkan in compassionate use has treated patients with a wide variety of cancers.
Whether it gets the label, or not, in the UK oncologists will be able to apply for the use of DCVax-L for their patients, that's not saying that all will be approved, just that they can apply. I would believe that the more who are successful the more likely that most, if not all, will be approved.
Gary
Bullish
Market Data 
Markets 
AI
